354 related articles for article (PubMed ID: 15709885)
41. Factors associated with preference for sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy: post hoc analysis of data from a multicentre, randomized, open-label, crossover study.
Eardley I; Montorsi F; Jackson G; Mirone V; Chan ML; Loughney K; Vail GM; Beardsworth A
BJU Int; 2007 Jul; 100(1):122-9. PubMed ID: 17552960
[TBL] [Abstract][Full Text] [Related]
42. Management of ED under the "severe distress" criteria in the NHS: a real-life study.
Mohee A; Bretsztajn L; Storey A; Eardley I
J Sex Med; 2014 Apr; 11(4):1056-1062. PubMed ID: 24382018
[TBL] [Abstract][Full Text] [Related]
43. Erectile dysfunction following radical retropubic prostatectomy: epidemiology, pathophysiology and pharmacological management.
Nandipati KC; Raina R; Agarwal A; Zippe CD
Drugs Aging; 2006; 23(2):101-17. PubMed ID: 16536634
[TBL] [Abstract][Full Text] [Related]
44. Prevalence and medical management of erectile dysfunction in Asia.
Park K; Hwang EC; Kim SO
Asian J Androl; 2011 Jul; 13(4):543-9. PubMed ID: 21460862
[TBL] [Abstract][Full Text] [Related]
45. Vardenafil: a review of its use in erectile dysfunction.
Keating GM; Scott LJ
Drugs; 2003; 63(23):2673-703. PubMed ID: 14636086
[TBL] [Abstract][Full Text] [Related]
46. A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient?
Hatzimouratidis K; Hatzichristou DG
Drugs; 2005; 65(12):1621-50. PubMed ID: 16060698
[TBL] [Abstract][Full Text] [Related]
47. New phosphodiesterase inhibitors in the treatment of erectile dysfunction.
Anderson PC; Gommersall L; Hayne D; Arya M; Patel HR
Expert Opin Pharmacother; 2004 Nov; 5(11):2241-9. PubMed ID: 15500370
[TBL] [Abstract][Full Text] [Related]
48. A randomized open-label trial with a crossover comparison of sexual self-confidence and other treatment outcomes following tadalafil once a day vs. tadalafil or sildenafil on-demand in men with erectile dysfunction.
Rubio-Aurioles E; Porst H; Kim ED; Montorsi F; Hackett G; Morales AM; Stuckey B; Būttner H; West TM; Huynh NN; Lenero E; Burns P; Kopernicky V
J Sex Med; 2012 May; 9(5):1418-29. PubMed ID: 22429760
[TBL] [Abstract][Full Text] [Related]
49. Erectile response to vardenafil in men with a history of nonresponse to sildenafil: a time-from-dosing descriptive analysis.
Hatzichristou DG; Aliotta P; Auerbach S; Barkin J; Lording D; Murdock M; Wilkins HJ; McBride TA; Colopy MW; Carson CC;
Clin Ther; 2005 Sep; 27(9):1452-61. PubMed ID: 16291418
[TBL] [Abstract][Full Text] [Related]
50. 10-Year analysis of adverse event reports to the Food and Drug Administration for phosphodiesterase type-5 inhibitors.
Lowe G; Costabile RA
J Sex Med; 2012 Jan; 9(1):265-70. PubMed ID: 22023666
[TBL] [Abstract][Full Text] [Related]
51. Phosphodiesterase-5 inhibitors and their hemodynamic effects.
Prisant LM
Curr Hypertens Rep; 2006 Aug; 8(4):345-51. PubMed ID: 16884667
[TBL] [Abstract][Full Text] [Related]
52. Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability.
Wang R; Burnett AL; Heller WH; Omori K; Kotera J; Kikkawa K; Yee S; Day WW; DiDonato K; Peterson CA
J Sex Med; 2012 Aug; 9(8):2122-9. PubMed ID: 22759639
[TBL] [Abstract][Full Text] [Related]
53. Psychosocial outcomes and drug attributes affecting treatment choice in men receiving sildenafil citrate and tadalafil for the treatment of erectile dysfunction: results of a multicenter, randomized, open-label, crossover study.
Dean J; Hackett GI; Gentile V; Pirozzi-Farina F; Rosen RC; Zhao Y; Warner MR; Beardsworth A
J Sex Med; 2006 Jul; 3(4):650-661. PubMed ID: 16839321
[TBL] [Abstract][Full Text] [Related]
54. Investigating women's preference for sildenafil or tadalafil use by their partners with erectile dysfunction: the partners' preference study.
Conaglen HM; Conaglen JV
J Sex Med; 2008 May; 5(5):1198-1207. PubMed ID: 18312284
[TBL] [Abstract][Full Text] [Related]
55. The Global Online Sexuality Survey (GOSS): the United States of America in 2011 chapter II: phosphodiesterase inhibitors utilization among English speakers.
Shaeer O
J Sex Med; 2013 Feb; 10(2):532-40. PubMed ID: 23088586
[TBL] [Abstract][Full Text] [Related]
56. Comparing vardenafil and sildenafil in the treatment of men with erectile dysfunction and risk factors for cardiovascular disease: a randomized, double-blind, pooled crossover study.
Rubio-Aurioles E; Porst H; Eardley I; Goldstein I
J Sex Med; 2006 Nov; 3(6):1037-1049. PubMed ID: 17100937
[TBL] [Abstract][Full Text] [Related]
57. Successful use of phosphodiesterase type 5 inhibitors to control symptomatic esophageal hypercontractility: a case report.
Agrawal A; Tutuian R; Hila A; Castell DO
Dig Dis Sci; 2005 Nov; 50(11):2059-62. PubMed ID: 16240215
[No Abstract] [Full Text] [Related]
58. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.
Gacci M; Corona G; Salvi M; Vignozzi L; McVary KT; Kaplan SA; Roehrborn CG; Serni S; Mirone V; Carini M; Maggi M
Eur Urol; 2012 May; 61(5):994-1003. PubMed ID: 22405510
[TBL] [Abstract][Full Text] [Related]
59. Novel PDE5 inhibitors for the treatment of male erectile dysfunction.
Kalsi JS; Bahadur G; Muneer A; Ozturk O; Christopher N; Ralph DJ; Minhas S
Reprod Biomed Online; 2003; 7(4):456-61. PubMed ID: 14656408
[TBL] [Abstract][Full Text] [Related]
60. [Birthday of a "potency pill". Helmut Newton celebrates posthumously likewise].
Keil TU
MMW Fortschr Med; 2004 Jul; 146(29-30):61. PubMed ID: 15540567
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]